Mathieu Verbrugghe1, Veerle Duprez, Dimitri Beeckman, Mieke Grypdonck, Marijke Quaghebeur, Caroline Verschueren, Sofie Verhaeghe, Ann Van Hecke. 1. Author Affiliations: University Centre for Nursing and Midwifery, Department of Public Health, Faculty of Medicine and Health Sciences, Ghent University, Ghent (Mr Verbrugghe, Ms Duprez, and Drs Beeckman, Grypdonck, Verhaeghe, and Van Hecke); Department of Hematology, University Hospital Ghent, Ghent (Marijke Quaghebeur); Department of Head and Neck Cancer, University Hospital Antwerp, Antwerp, Belgium (Dr Verschueren).
Abstract
BACKGROUND: Nonadherence in cancer patients taking oral anticancer drugs is common. Reasons for nonadherence are still not really understood as influencing factors are often complex, dynamic, and interrelated. OBJECTIVE: A qualitative study was conducted to gain insight into (non-)adherence behavior in patients taking oral tyrosine kinase inhibitors by exploring (1) processes and factors influencing (non-)adherence and (2) their interrelatedness. METHODS: Semistructured interviews were held with 30 patients of different ages and with different types of cancer. A grounded theory approach was used. RESULTS: Three foci were found when dealing with oral tyrosine kinase inhibitors: (1) a focus on survival, (2) a focus on quality of life, and (3) a balance between survival and quality of life. The process of adherence was determined by a set of complex and interrelated influencing factors: treatment-related side effects, hope, anxiety, trust, and feedback mechanisms. CONCLUSIONS: This qualitative study gives insight into processes and factors influencing (non-)adherence behavior in patients taking oral tyrosine kinase inhibitors. The results of this study can help healthcare professionals understand why patients taking oral tyrosine kinase inhibitors do not always adhere to their therapy. IMPLICATIONS FOR PRACTICE: Conditions should be created by which patients get maximum opportunity to establish a balance between survival and quality of life. An open climate and a trust-based relationship should be established in which patients feel comfortable to openly discuss their therapy and the difficulties they experience.
BACKGROUND: Nonadherence in cancerpatients taking oral anticancer drugs is common. Reasons for nonadherence are still not really understood as influencing factors are often complex, dynamic, and interrelated. OBJECTIVE: A qualitative study was conducted to gain insight into (non-)adherence behavior in patients taking oral tyrosine kinase inhibitors by exploring (1) processes and factors influencing (non-)adherence and (2) their interrelatedness. METHODS: Semistructured interviews were held with 30 patients of different ages and with different types of cancer. A grounded theory approach was used. RESULTS: Three foci were found when dealing with oral tyrosine kinase inhibitors: (1) a focus on survival, (2) a focus on quality of life, and (3) a balance between survival and quality of life. The process of adherence was determined by a set of complex and interrelated influencing factors: treatment-related side effects, hope, anxiety, trust, and feedback mechanisms. CONCLUSIONS: This qualitative study gives insight into processes and factors influencing (non-)adherence behavior in patients taking oral tyrosine kinase inhibitors. The results of this study can help healthcare professionals understand why patients taking oral tyrosine kinase inhibitors do not always adhere to their therapy. IMPLICATIONS FOR PRACTICE: Conditions should be created by which patients get maximum opportunity to establish a balance between survival and quality of life. An open climate and a trust-based relationship should be established in which patients feel comfortable to openly discuss their therapy and the difficulties they experience.
Authors: Christel C L M Boons; Lonneke Timmers; Natasja M van Schoor; Eleonora L Swart; N Harry Hendrikse; Jeroen J W M Janssen; Jacqueline G Hugtenburg Journal: Cancer Med Date: 2017-11-23 Impact factor: 4.452
Authors: Amparo Talens; Mercedes Guilabert; Blanca Lumbreras; María Teresa Aznar; Elsa López-Pintor Journal: Int J Environ Res Public Health Date: 2021-04-17 Impact factor: 3.390
Authors: Lonneke Timmers; Christel C L M Boons; Mathieu Verbrugghe; Bart J F van den Bemt; Ann Van Hecke; Jacqueline G Hugtenburg Journal: BMC Cancer Date: 2017-02-10 Impact factor: 4.430
Authors: Margherita Nannini; Maria Concetta Nigro; Bruno Vincenzi; Elena Fumagalli; Giovanni Grignani; Lorenzo D'Ambrosio; Giuseppe Badalamenti; Lorena Incorvaia; Raffaella Bracci; Silvia Gasperoni; Maristella Saponara; Lidia Gatto; Valentina Indio; Annalisa Astolfi; Valerio Di Scioscio; Paolo G Casali; Giuseppe Tonini; Massimo Aglietta; Antonio Russo; Guido Biasco; Maria A Pantaleo Journal: Ther Adv Med Oncol Date: 2017-12-19 Impact factor: 8.168
Authors: Kai Qi Elizabeth Peh; Yu Heng Kwan; Hendra Goh; Hasna Ramchandani; Jie Kie Phang; Zhui Ying Lim; Dionne Hui Fang Loh; Truls Østbye; Dan V Blalock; Sungwon Yoon; Hayden Barry Bosworth; Lian Leng Low; Julian Thumboo Journal: J Gen Intern Med Date: 2021-03-03 Impact factor: 5.128